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ABSTRACT: Respiratory insufficiency due to respiratory syncytial virus (RSV)
bronchiolitis is partly due to the abundance of thickened mucus and the inability to clear
it from the airways. Mucus in RSV bronchiolitis contains necrotic inflammatory and
epithelial cells. The viscoelastic properties of purulent airway secretions are largely due
to the presence of highly polymerized deoxyribonucleic acid (DNA). Recombinant
human deoxyribonuclease (rhDNase) is known to liquefy such mucus in patients with
cystic fibrosis, whereas case reports described a beneficial effect in other respiratory
disorders. The authors hypothesized that rhDNase would diminish atelectasis and
mucus plugging in infants with severe RSV bronchiolitis.
Two infants with RSV bronchiolitis with massive unilateral atelectasis in whom
mechanical ventilation was imminent due to exhaustion, and three mechanically
ventilated infants (two neonates, one with bronchopulmonary dysplasia) with RSV
bronchiolitis with pneumonia received treatment with 2.5 mg nebulized rhDNase twice
daily.
Following administration of nebulized recombinant human deoxyribonuclease,
clinical and radiological parameters improved quickly. Mechanical ventilation could
be avoided in two infants while in three infants on artificial ventilation, clinical recovery
started following the first dose of the drug. A therapeutic trial of recombinant human
deoxyribonuclease may be an option in the treatment for atelectasis in severe or
complicated respiratory syncytial virus bronchiolitis in infancy.
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Respiratory syncytial virus (RSV) bronchiolitis is
one of the main causes of hospital admissions in
neonates and infants and is responsible for substantial
morbidity and mortality [1]. Treatment basically
consists of supportive measures, as current therapeutic
options in otherwise healthy infants are ineffective or
controversial [2–4]. Complications include atelectasis,
ventilation/perfusion mismatch, and respiratory in-
sufficiency requiring mechanical ventilation (MV).
In children with an increased risk of severe RSV
bronchiolitis (neonates born prematurely and with
chronic cardiopulmonary or neuromuscular diseases)
MV may be difficult to avoid.
Respiratory failure due to RSV bronchiolitis is
mainly due to the abundance and retention of thick-
ened mucus. The viscoelastic properties of purulent
airway secretions depend primarily on the presence
of highly polymerized, polyanionic deoxyribonucleic
acid (DNA), often as extracellular fibrils [5], mostly
from degenerating leukocytes [6]. Recombinant
human deoxyribonuclease (rhDNase) liquefies mucus
in vitro within minutes, transforming it from a viscous
gel to a flowing liquid [5–8]. Its efficacy has been well
documented in cystic fibrosis [5–8], whereas case
reports have described beneficial effects of rhDNase
on the resolution of atelectasis in asthma, spinal cord
injury, and primary ciliary dyskinesia [9–15]. Because
mucus in RSV bronchiolitis contains necrotic inflam-
matory and epithelial cells [2], rhDNase may also be
expected to be effective in RSV bronchiolitis.
The authors report their experience with nebulized
rhDNase in the treatment of atelectasis in five infants
with severe or complicated RSV bronchiolitis.
Case report
Patient 1
A term female baby developed RSV bronchiolitis at
5 weeks of age. The patient was transferred to the
paediatric intensive care unit because of a deteriorat-
ing clinical condition. At admission, the chest radio-
graph showed partial atelectasis of the right lung
with the carbon dioxide tension in arterial blood
(Pa,CO2) up to 12 kPa (90 mmHg). Additional oxygen
(2 L?min-1) was required through nasal prongs.
Nebulized bronchodilator drugs and physiotherapy
had no effect. The atelectasis of the right lung
progressed 1 day later, with mediastinal herniation
of the left lung and a shift of the trachea and
mediastinum to the right side (fig. 1a). This suggested
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blockage of the right main stem bronchus, probably
due to mucus plugging. Because signs of fatigue were
shown, artificial ventilation seemed imminent. Thera-
peutic bronchoscopy was considered, but this would
have increased the risk of subsequent MV. Therefore,
attempts were made to liquefy any viscous mucus and
improve mucus clearance by administration of 2.5 mg
rhDNase (Pulmozyme1, Roche, Basel, Switzerland),
using a jet nebulizer.
Within 3 h of this treatment, ventilation improved,
breathing sounds returned to the right lung, hyper-
capnia decreased to 6.9 kPa (52 mmHg) and the chest
radiograph showed aeration of the right upper and
lower lobes again, with less mediastinal shift or
herniation of the left lung. Following continued
treatment of rhDNase 2.5 mg twice daily for 2 days,
the child recovered and the chest radiograph showed
further improvement (fig. 1b). Artificial ventilation or
bronchoscopy were not needed. No side-effects were
observed. Because of a weak coughing reflex and
feeding difficulties the patient was hospitalized for 2
weeks. At the age of 10 weeks a diagnosis of spinal
muscular atrophy was made, partly explaining the
dramatic course of RSV bronchiolitis.
Patient 2
A term female baby had no illnesses until 7 weeks of
age, when the patient became progressively dyspnoeic
due to RSV bronchiolitis. Additional oxygen was
required and the patient was hospitalized. Nebulized
bronchodilator drugs and physiotherapy did not
improve the airways obstruction. The clinical condi-
tion deteriorated and 1 day later, a chest radiograph
showed a complete atelectasis of the right lung, with
volume loss and a mediastinal shift. Because MV was
imminent, the patient was transferred to the neonatal
intensive care unit and a therapeutic trial with 2.5 mg
nebulized rhDNase was administered twice daily in an
attempt to avoid artificial ventilation. Within 6 h of
the first dose, the breathing frequency decreased from
95 to 39 min-1 with less dyspnoea, and the cardiac
frequency decreased from 182 to 164 beats?min-1.
Breathing sounds on the right lower lobe improved
and the supply of oxygen could be tapered off. Twenty
hours later, the chest radiograph showed marked
improvement. MV was not needed and further clini-
cal treatment was only indicated because of feeding
difficulties due to RSV rhinitis. The patient was
discharged on day 9. At 6 months of age the patient9s
condition is fine and no underlying illness has been
found.
Because of these observations in two infants with
severe RSV bronchiolitis in whom artificial ventilation
was avoided, rhDNase was administered in three
other infants who were on MV due to complicated
RSV bronchiolitis (table 1). Patients 3 and 5 devel-
oped bronchiolitis neonatally, and patient 4 had
chronic lung disease following prematurity. They all
had complicating pneumoniae with positive cultures
for Streptococcus pneumoniae. A therapeutic trial of
rhDNase was given because ventilator settings were
high and the clinical condition did not improve. No
side-effects were observed. Within 24 h of the treat-
ment, chest radiographs, cardiac frequency and Pa,CO2
improved. Peak inspiratory pressures and the inspira-
tory oxygen fraction (FI,O2) did not change signifi-
cantly (table 1).
Discussion
This report is the first to suggest that rhDNase is
effective and safe in the mobilization of mucus in
infant RSV bronchiolitis. The efficacy of rhDNase
in cystic fibrosis has been proven [5–8], and case
reports strongly suggest its efficacy on the resolution
of atelectasis in various other respiratory disorders
[9–15]. The present observation of resolution of
atelectasis and clinical improvement immediately
following nebulized rhDNase is consistent with these
reports. The regular dose of nebulized rhDNase of
2.5 mg was administered in all patients. Assuming a
a) b)
Fig. 1. – a) Complete atelectasis of the right lung, with rightward mediastinal shift and herniation of the left lung due to severe respiratory
syncytial virus bronchiolitis before recombinant human deoxyribonuclease treatment in patient 1. b) Improved aeration of both lungs, less
bronchitic markings and residual atelectasis of the right upper lobe, after 36 h (3 doses of recombinant human deoxyribonuclease) in
patient 1.
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lung dose of 5–10% in the absence of airway obstruc-
tion, this dose is probably low compared to the studies
by DURWARD et al. [15] and by BOEUF et al. [16] in
which doses of instilled rhDNase were 0.5 mg?kg
body weight-1, and 4 mg?m-2. None of the papers
mentioned earlier reported any side-effects. The
main arguments for trying rhDNase in the unventi-
lated children were the reported presence of necrotic
epithelial cells and leukocytes in RSV-induced airway
secretions [2], and the progressive respiratory failure,
while conventional treatment was ineffective and
therapeutic bronchoscopy not attractive.
In the three ventilated patients clinical improvement
was also seen following rhDNase treatment, although
it was less pronounced than in the unventilated
infants. This may be partly explained by the compli-
cating pneumonia in the ventilated infants. Paren-
chymal consolidation due to infection is unlikely to
improve using rhDNase, whereas airway collapse
may improve rather quickly following liquefaction
of thickened mucus. Marked improvement was seen
in the chest radiograph, cardiac frequency and Pa,CO2.
Peak inspiratory pressure did not change much, which
may be attributed to a loss of compliance due to the
course of the RSV bronchiolitis and the complicating
pneumonia. FI,O2 did not decrease markedly, which is
consistent with persisting ventilation/perfusion mis-
match due to pneumonia. Duration of ventilation
was longer (5 days compared to 1 day) and effect of
rhDNase treatment was less clear in patient 5
compared to patients 3 and 4. Possibly, ventilation
period and/or the timing of rhDNase administration
are factors that codetermine the treatment result.
Obviously, controlled studies are needed to assess
the efficacy and safety of the drug for treatment of
atelectasis and mucus plugging in severe respiratory
syncytial virus bronchiolitis. Respiratory syncytial
virus epidemics still constitute a significant burden
on patients, families and paediatric healthcare re-
sources. This case report highlights a possible novel
therapeutic option in the treatment of one of the most
notorious respiratory infections of infancy. Until
randomized trials have been performed, the authors
suggest considering a therapeutic trial of recombinant
human deoxyribonuclease in those infants who
develop massive atelectasis due to severe or compli-
cated respiratory syncytial virus bronchiolitis.
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